H.B. Fuller Revenue Miss Overshadows Profit Beat as Acquisition Concerns Weigh on Stock

H.B. Fuller (NYSE: FUL) shares are trading near a 52-week low despite the company reporting another quarter of better-than-expected earnings, as a miss on revenue and concerns over a major pending acquisition weigh heavily on investor sentiment.

A Mixed Third-Quarter Report

The adhesives manufacturer reported third-quarter adjusted earnings per share of $1.52, beating analyst estimates of $1.47, according to Investing.com data. However, quarterly revenue of $938 million fell short of the projected $948.25 million.

This top-line miss suggests that the volume headwinds management had previously warned of are beginning to materialize, overshadowing the company's operational strength in managing costs. The stock fell 3.29% in trading on September 24, extending its three-month decline to nearly 25%.

Acquisition Overhang Dominates

The primary factor pressuring the stock is the planned £715 million (approximately $1 billion) all-cash acquisition of UK-based Advanced Medical Solutions (AMS). Investors are scrutinizing the deal's financial implications, which include:

Ad

• A significant increase in leverage to approximately 4x net debt-to-EBITDA upon closing, up from 3.1x and well above the company's target range of 2.5–3x.
• A long timeline for realizing the projected $55 million in cost synergies, which are not expected to be fully achieved until 2030.
• Deal risk sitting entirely with H.B. Fuller, as the agreement includes no breakup fee under the UK's Takeover Code.

These concerns were significant enough to drive an 8.2% stock decline after the company's strong second-quarter results in June, and they continue to influence market perception.

Key Catalysts Ahead

Looking forward, the market is focused on several key developments. The closure of the AMS acquisition, expected by the end of calendar 2026, remains the most immediate hurdle. A smooth closing could remove a significant overhang, while any delays could add to uncertainty.

Investors will also be closely watching for definitive evidence on volume trends in the fourth quarter, particularly in the Hygiene, Health & Consumables (HHC) segment, which management has identified as vulnerable to consumer destocking. Analyst outlooks remain divided, with UBS citing acquisition risk for its Neutral rating, while JPMorgan focuses on underlying earnings momentum for its Overweight rating.